TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35504550

Group type: COMPARATOR
Intervention: Topical antiviral therapy (TAT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical antiviral therapy + adjunctive antimicrobial photodynamic therapy (TAT + aPDT)
Number of subjects: 45
Study: 35288009

Group type: EXPERIMENTAL
Intervention: 5 ml/kg carbohydrate (≤400 ml) 2 hours before surgery
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fasting for 6 hours and forbidden from drinking water for 4 hours before surgery
Number of subjects: 86
Study: 34619044

Group type: EXPERIMENTAL
Intervention: CBD (300 mg daily for 14 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (added to standard symptomatic care for 14 days)
Number of subjects: 105
Study: 32574506

Group type: EXPERIMENTAL
Intervention: HBOT-EMI (Hyperbaric Oxygen Therapy and Exercise and Mental Imagery)
Number of subjects: 27

Group type: COMPARATOR
Intervention: EMI alone (Control)
Number of subjects: 27
Study: 35379762

Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: fingolimod
Number of subjects: 1830

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1830
Study: 33662265

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 348

Group type: COMPARATOR
Intervention: No SMS reminders
Number of subjects: 348
Study: 32859658

Group type: COMPARATOR
Intervention: Healthcare use (HCU) at baseline
Number of subjects: 443
Study: 35201404

Group type: EXPERIMENTAL
Intervention: Continued CPAP
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 37
Study: 33431386

Group type: EXPERIMENTAL
Intervention: interactive e‐consent
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: trust‐enhanced e‐consent
Number of subjects: 734

Group type: COMPARATOR
Intervention: standard e‐consent
Number of subjects: 734
Study: 34375409

Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention (TMI) - 174 automated text messages plus a group smoking counseling session and provision of nicotine patches
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention (TMI)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (Standard Care)
Number of subjects: 77
Study: 34569204

Group type: EXPERIMENTAL
Intervention: Acupoint application of Chinese herbal medicine (Rhizome Pinelliae Preparata, Ginger, Clove) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group received placebo plasters (flour and excipients with 10% of experimental drug concentration) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Number of subjects: 168
Study: 32083686

Group type: COMPARATOR
Intervention: White male physician (control)
Number of subjects: 3592

Group type: EXPERIMENTAL
Intervention: White female physician
Number of subjects: 3592

Group type: EXPERIMENTAL
Intervention: Black female physician
Number of subjects: 3592

Group type: EXPERIMENTAL
Intervention: Black male physician
Number of subjects: 3592
Study: 35887701

Group type: EXPERIMENTAL
Intervention: Repetitive vascular occlusion stimulus (RVOS) applied twice daily for 10 days (4 cycles of 5 min tourniquet inflation to 50 mmHg supra-systolic blood pressure, and 5 min complete deflation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repetitive vascular occlusion stimulus (RVOS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12
Study: 34237973

Group type: EXPERIMENTAL
Intervention: Vancomycin-loaded calcium phosphate cement (CPC) after debridement
Number of subjects: 98

Group type: COMPARATOR
Intervention: Irrigation and drainage device with irrigated antibiotics
Number of subjects: 98
Study: 35565826

Group type: EXPERIMENTAL
Intervention: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP) for 5 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP)
Number of subjects: 49
Study: 33559686

Group type: EXPERIMENTAL
Intervention: Guided insertion of Ambu AuraGain™
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-guided insertion of Ambu AuraGain™
Number of subjects: 72
Study: 36169949

Group type: COMPARATOR
Intervention: Single vision contact lenses
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: +2.50 D addition multifocal contact lenses
Number of subjects: 294
Study: 33846036

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Symptomatic care and specific therapies (including intravenous aminophylline)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Polyvalent immunoglobulins
Number of subjects: 2
Study: 35865740

Group type: EXPERIMENTAL
Intervention: 3% Kānuka oil cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 80
Study: 32965075

Group type: EXPERIMENTAL
Intervention: PEX168/100 μg
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: PEX168/200 μg
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 615917877

Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab (IVR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IVR-PASCAL (Panphotocoagulation with PASCAL laser)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IVR-EDTRS (Panphotocoagulation with EDTRS laser)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (IVR alone)
Number of subjects: 44
Study: 34281305

Group type: EXPERIMENTAL
Intervention: Intra-pocket delivery of Grape Seed Extract (GSE) with Scaling and Root Planing (SRP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) alone
Number of subjects: 72
Study: 32678914

Group type: EXPERIMENTAL
Intervention: MI varnish containing casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) and 2.26% fluoride
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Duraphat varnish containing 2.26% fluoride
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo varnish (no added calcium or fluoride)
Number of subjects: 2
Study: 36057489

Group type: EXPERIMENTAL
Intervention: Heliox (80/20%)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Air
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Heliox responders (FEV1 improvement >10%)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Heliox non-responders
Number of subjects: 53
Study: 34812136

Group type: EXPERIMENTAL
Intervention: 6-month psychosocial intervention
Number of subjects: 402

Group type: COMPARATOR
Intervention: brief psychoeducational intervention
Number of subjects: 402
Study: 36382449

Group type: EXPERIMENTAL
Intervention: Domestic PEEK suture anchors (REJOIN Company)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Imported PEEK suture anchors (American Arthrex Company)
Number of subjects: 55
Study: 35297777

Group type: EXPERIMENTAL
Intervention: MyCourse (digital, minimally guided smoking cessation intervention)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (noninteractive web-based information brochure)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: MyCourse
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study: 33606901

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop with faster-acting insulin aspart (Fiasp)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hybrid closed-loop with standard insulin aspart
Number of subjects: 25
Study: 35491363

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 325
Study: 33265967

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Diet Score (mMDS)
Number of subjects: 460
Study: 36323602

Group type: EXPERIMENTAL
Intervention: Sublingual melatonin 3 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32894075

Group type: EXPERIMENTAL
Intervention: Web-based cognitive training targeting working memory updating (30 sessions over 6-8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low dose short-term memory program (placebo control)
Number of subjects: 80
Study: 35714715

Group type: EXPERIMENTAL
Intervention: Simultaneous ulnar and radial artery compression (SURC), Group C
Number of subjects: 450

Group type: COMPARATOR
Intervention: Conventional hemostasis, Group A
Number of subjects: 450

Group type: COMPARATOR
Intervention: Patent hemostasis, Group B
Number of subjects: 450
Study: 32824483

Group type: EXPERIMENTAL
Intervention: 90 mg AME
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 150 mg AME
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 34151868

Group type: EXPERIMENTAL
Intervention: Self-inflating bag (SIB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: T-piece (TP)
Number of subjects: 20
Study: 34022425

Group type: EXPERIMENTAL
Intervention: Digital literacy promotion (DLP) using e‐books
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard literacy promotion (SLP) using board books
Number of subjects: 104
Study: 32486622

Group type: EXPERIMENTAL
Intervention: Intervention group (IPE program)
Number of subjects: 116
Study: 35749486

Group type: EXPERIMENTAL
Intervention: 100% oxygen delivered by a face mask with reservoir
Number of subjects: 15

Group type: COMPARATOR
Intervention: Room air delivered by a face mask with reservoir
Number of subjects: 15
Study: 33797785

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stabilisation Splint (SS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Therapy (CT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-Frequency Parafunction (HFP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-Frequency Parafunction (LFP)
Number of subjects: 45
Study: 32211767

Group type: COMPARATOR
Intervention: 0 mg Cr/d from Cr Prop
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2 mg Cr/d from Cr Prop
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 4 mg Cr/d from Cr Prop
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 8 mg Cr/d from Cr Prop
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2 or 4 mg Cr/d from Cr Prop
Number of subjects: 48
Study: 34037752

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no testosterone treatment)
Number of subjects: 0
Study: 35014110

Group type: EXPERIMENTAL
Intervention: Extreme E2 group (first-time pregnant women)
Number of subjects: 44

Group type: COMPARATOR
Intervention: High E2 group (12 mg of E2 valerate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low E2 group (placebo)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Extreme E2 group
Number of subjects: 44
Study: 35915368

Group type: EXPERIMENTAL
Intervention: Facility-based multidomain intervention (FMI)
Number of subjects: 152
Study: 34085585

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) at 200 μg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study: 35597370

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid supplementation to rescue therapy
Number of subjects: 990
Study: 32696210

Group type: EXPERIMENTAL
Intervention: Total-etch (TE) technique with 37% phosphoric acid etching
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self-etch (SE) technique with no prior etching
Number of subjects: 35
Study: 32886668

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 98

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 98
Study: 34642949

Group type: EXPERIMENTAL
Intervention: ASP0367 (bocidelpar sulfate) single doses of 1 to 120 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ASP0367 (bocidelpar sulfate) multiple once-daily doses of 10 to 75 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ASP0367 (bocidelpar sulfate)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 35133996

Group type: EXPERIMENTAL
Intervention: ShoulderSphere (SS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TheraBand (TB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study: 36093695

Group type: EXPERIMENTAL
Intervention: Nichi Glucan 0.5g twice daily along with conventional treatment for 90 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional treatment comprising remedial behavioral therapies and L-carnosine 500 mg per day
Number of subjects: 18
Study: 34435804

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 134
Study: 32732336

Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of NG infection
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Time to clearance
Number of subjects: 720

Group type: COMPARATOR
Intervention: Chlamydia coinfection
Number of subjects: 720

Group type: COMPARATOR
Intervention: Dysuria
Number of subjects: 720
Study: 36381204

Group type: EXPERIMENTAL
Intervention: Intra-sacroiliac joint methylprednisolone injection (40 mg) plus NSAIDs and sulfasalazine (2 to 3 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone injection)
Number of subjects: 60
Study: 32108545

Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (leg press)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (elbow flexion contralateral)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (elbow flexion affected arm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (elbow extension)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (shoulder abduction contralateral)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (shoulder abduction affected arm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Test battery of dynamic muscle tests
Number of subjects: 15
Study: 35801307

Group type: EXPERIMENTAL
Intervention: Virtual patient computer simulation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Written simulation
Number of subjects: 204

Group type: COMPARATOR
Intervention: No simulation control group
Number of subjects: 204
Study: 34022938

Group type: EXPERIMENTAL
Intervention: PPM6: performance of two 30 min of cycling desk (using portable pedal exercise machine—PPM) per working day for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: CTL_PPM3: 3 months with no intervention (control) followed by 3 months during which workers will be asked to complete two 30 min of PPM per working day
Number of subjects: 80
Study: 32145825

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 70 mg/m2 or carboplatin AUC4.5/AUC5 for GFR <50 mL/min, plus gemcitabine 1000 mg/m2 on days 1 and 8)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 261
Study: 36223044

Group type: EXPERIMENTAL
Intervention: Parent Connext intervention (integrates adversity screening and parent coaching)
Number of subjects: 27419

Group type: EXPERIMENTAL
Intervention: Parent Connext intervention
Number of subjects: 27419

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 27419
Study: 33892269

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 500

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) and Yoga
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 500
Study: 35244504

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 38
Study: 34197589

Group type: EXPERIMENTAL
Intervention: Dopamine D2/3 receptor antagonist amisulpride (400 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dopamine D2/3 receptor agonist pramipexole (0.5 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 32075830

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 20 mg per day for 5 days
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 36088627

Group type: EXPERIMENTAL
Intervention: Intralesional Vitamin D3
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 100
Study: 32811623

Group type: EXPERIMENTAL
Intervention: XR-NTX only
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: XR-NTX + PN
Number of subjects: 135

Group type: COMPARATOR
Intervention: Enhanced Treatment-as-Usual (ETAU)
Number of subjects: 135
Study: 33612554

Group type: EXPERIMENTAL
Intervention: 2nd-generation drug-eluting stents (n=59)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Bare metal stents (n=53)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both BMS and 2nd-generation DES
Number of subjects: 112

Group type: COMPARATOR
Intervention: Target vessels with BMS
Number of subjects: 112
Study: 34106454

Group type: EXPERIMENTAL
Intervention: ipilimumab-nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: platinum chemotherapy and durvalumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: tremelimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: chemo-immunotherapy
Number of subjects: 0
Study: 32346001

Group type: EXPERIMENTAL
Intervention: Statin therapy (60% of patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Follow-up measurement
Number of subjects: 90
Study: 34822104

Group type: EXPERIMENTAL
Intervention: Venetoclax (400-800 mg) administered with R-CHOP for eight 21-day cycles (cycle 1: days 4-10; cycles 2-8: days 1-10)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Venetoclax (400-800 mg)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg) with R-CHOP
Number of subjects: 216

Group type: COMPARATOR
Intervention: R-CHOP (historical control from GOYA study)
Number of subjects: 216
Study: 35363510

Group type: EXPERIMENTAL
Intervention: Selumetinib (MEK inhibitor), administered twice daily for 28-day cycles until disease progression or intolerable toxicity.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Selumetinib (MEK inhibitor)
Number of subjects: 20
Study: 35409821

Group type: EXPERIMENTAL
Intervention: One-day workshop for managers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 70
Study: 34809672

Group type: EXPERIMENTAL
Intervention: Active electronic alert for sepsis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Masked alert (control)
Number of subjects: 45
Study: 32611826

Group type: EXPERIMENTAL
Intervention: Persian version of State-Trait Anxiety Inventory (STAI-Y)
Number of subjects: 492
Study: 35777775

Group type: EXPERIMENTAL
Intervention: Telephone lung cancer risk assessment with general practitioner endorsement and reminders
Number of subjects: 44943

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 44943
Study: 32565102

Group type: EXPERIMENTAL
Intervention: Exteroceptive and proprioceptive sensory stimulations for 6 weeks
Number of subjects: 60
Study: 34247027

Group type: EXPERIMENTAL
Intervention: Melissa essential oil (inhaled 2 drops for 10 min with 90-min intervals)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (sunflower oil inhaled 2 drops for 10 min with 90-min intervals)
Number of subjects: 72
Study: 33242775

Group type: EXPERIMENTAL
Intervention: MINDSET plus Usual Care (n = 46)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual Care Only (n = 48)
Number of subjects: 94
Study: 34619500

Group type: EXPERIMENTAL
Intervention: Integrated CBT and acupressure (CBTAcup)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 40
Study: 34763045

Group type: EXPERIMENTAL
Intervention: Bufei Huoxue (BFHX)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 36089974

Group type: EXPERIMENTAL
Intervention: Martial arts routines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (traditional treatment)
Number of subjects: 0
Study: 33245118

Group type: EXPERIMENTAL
Intervention: Financial incentives for dietary self-monitoring and weekly weight loss
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (Cohort 1)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Reduced-calorie diet (Cohort 2)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (Cohort 3)
Number of subjects: 93
Study: 34871550

Group type: EXPERIMENTAL
Intervention: Carfilzomib, daratumumab, and dexamethasone (KdD)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 466
Study: 33879352

Group type: EXPERIMENTAL
Intervention: Active TENS + Active JM
Number of subjects: 144

Group type: COMPARATOR
Intervention: Active TENS + Placebo JM
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo TENS + Active JM
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo TENS + Placebo JM
Number of subjects: 144
Study: 34456322

Group type: EXPERIMENTAL
Intervention: Myofascial facial massage
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Various massage techniques for facial muscle relaxation
Number of subjects: 151
Study: 33275467

Group type: EXPERIMENTAL
Intervention: Resistance exercise for 60 minutes, 2 days a week, for 3 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 39
Study: 32033582

Group type: EXPERIMENTAL
Intervention: Buprenorphine (10 μg/kg or 15 μg/kg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Naloxone (titrated doses)
Number of subjects: 85
Study: 34705168

Group type: EXPERIMENTAL
Intervention: FiO2 of 0.8 (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: FiO2 of 0.6 (Group 2)
Number of subjects: 30
Study: 33944597

Group type: EXPERIMENTAL
Intervention: Vaccine A (2 mL, 1 mL/nostril)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vaccine B (2 mL, 1 mL/nostril)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (0.9% NaCl) solution (2 mL)
Number of subjects: 90